MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia"

  • 2025 International Congress

    Prevalence, demographic characteristics of Parkinson disease and associated comorbidities: An analysis of the Colombian Ministry of Health official registry

    A. Rincon, C. Pantoja, J. Torres, C. Tamayo, D. Rosselli (Bogotá, Colombia)

    Objective: Conduct a descriptive analysis of the Colombian Parkinson’s disease population and its comorbidities using data from the Colombian Ministry of Health.Estimate the prevalence and…
  • 2025 International Congress

    Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics

    K. Luk, B. Li, S. Song, N. Newman (Cambridge, USA)

    Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…
  • 2025 International Congress

    The Movement Disorders Society Unified Parkinson Disease Rating Scale Motor Subscore Is Not Associated With Future Parkinson Disease Milestones – an observational study using linked health administrative data

    P. Gros, S. Bronskill, S. Dorrance, X. Wang, M. Chiu, M. Farkouh, C. Marras (Toronto, Canada)

    Objective: To examine the association between time to Parkinson Disease (PD) health administrative data milestones and a one-year change in the Movement Disorders Society –…
  • 2025 International Congress

    Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease

    T. Tropea, P. Aldea Stevenson, M. Flitter, D. Meehan, A. Morris, M. Lu, L. Iaccarino, E. Collins, M. Hodsdon, L. Shaw, E. Lee, D. Weintraub, A. Chen-Plotkin, M. Mintun, A. Siderowf (Philadelphia, USA)

    Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…
  • 2025 International Congress

    Multimodal Dissection of GALC Variants Linking Olfactory Deficits to Cognitive Decline in Parkinson’s Disease

    Y. Li, M. Zhong, J. Liu (shanghai, China)

    Objective: Olfactory dysfunction is highly prevalent and often precedes motor symptoms, making it a potential early biomarker for disease progression and cognitive decline in Parkinson's…
  • 2025 International Congress

    Metabolomics Profiling in Egyptian Patients with Alzheimer’s and Parkinson’s Diseases

    S. Abdelaziz, A. Helmy, E. Hamid, M. Salama, A. Shalash (Cairo, Egypt)

    Objective: To identify differential serum metabolites found in AD and PD patients and their correlations to clinical presentation in Egyptian patients. Background: There is a…
  • 2025 International Congress

    Neurodegeneration Biomarkers: Correlation between Hippocampal Volume and Cognitive Performance by MoCA Test in Parkinson’s Disease

    Y. Matuk Perez, E. Fernandez Calleja, D. Resendiz Gonzalez, JM. Esquivias Farías, S. Alcauter Solórzano, I. Zamorano-Rangel (Queretaro, Mexico)

    Objective: This study aims to examine the relationship between hippocampal volume, assessed through magnetic resonance imaging (MRI), and MoCA test scores in patients diagnosed with…
  • 2025 International Congress

    Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia

    F. Dino, L. Gunn-Sandell, A. Tsai, D. Carter, Y. Wang, E. Bayram (Aurora, USA)

    Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…
  • 2025 International Congress

    Association between cognitive adverse effects of anticholinergic medication and development of long-term dementia in Parkinson’s disease

    SH. Ha, BR. Jin, SY. Kim, SM. Lee, JH. Shin, HJ. Kim (Seoul, Republic of Korea)

    Objective: To investigate whether cognitive adverse effects occurring immediately after taking anticholinergics are related to the development of long-term dementia and to interpret this from…
  • 2025 International Congress

    Comparative Analysis of MoCA Scores Between Latin American Latinos and White Patients with Parkinson’s Disease

    S. Sperling, S. Anis, H. Mauricio Chaparro-Solano, T. Peixoto Leal, C. Sonneborn, C. Callegari Piccini, M. Inca-Martinez, M. Cornejo-Olivas, M. Illanes-Manrique, P. Chana-Cuevas, P. Safie Awad, A. Jimena Hernández-Medrano, A. Cervantes-Arriaga, A. Schuh, C. Rieder, P. Braga-Neto, A. Silva Sena, B. Lopes Santos-Lobato, E. Gatto, G. Alvarado, C. Avila, V. Tumas, M. Paula Foss, V. Borges, H. Ballalai Ferraz, J. Orozco Vélez, B. Muñoz Ospina, S. Moreno, D. Pineda, J. Rios Pinto, P. Olguín, J. Cristobal Nuñez, A. Viñuela, A. Espinal-Martinez, N. Mori, K. Mejía-Rojas, A. Medina-Colque, A. Zuma Rosso, C. Vilaça, E. Ochoa-Valle, I. Cornejo-Herrera, P. Reyes-Perez, A. Lázaro-Figueroa, A. Moraes Alves, R. Gisbert Cury, H. Fernandez, I. Mata (Cleveland, USA)

    Objective: The study objectives were to 1) characterize scores on the Montreal Cognitive Assessment (MoCA) in patients with Parkinson’s disease (PD) from Latin America, 2)…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 39
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley